Green Cross to emerge as forerunner in vaccine business

Published: 2009-05-14 06:59:00

Updated: 2009-05-14 06:59:00

Green Cross Corporation (GCC) is expected to become a leader in the new influenza vaccine sector as the Korean government plans to double its stockpile of Tamiflu and other influenza drugs, enough to treat 5 million people, around 10 percent of the country's population, according to a market anal...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK